FOLH1 and neoplasm: 18F labelled prostate-specific membrane antigen (PSMA)-1007 is a novel PSMA-based radiopharmaceutical, it was introduced into clinical practice because its excellent tumor uptake and high sensitivity for detecting lesions (5–7).